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HAS THE GWAS BEEN SUCCESSFUL?
T.D. Spector
King’s Coll. London, London, United Kingdom
Osteoarthritis (OA) is a common condition of bone and cartilage seriously
affecting one in four people aged over 60. It is now known to be strongly
heritable at all sites measured with estimates ranging from 40-65% heri-
tability. Upto recently the main studies available for gene discovery were
candidate genes and Linkage studies. Linkage studies have shown large ar-
eas of chromosomes associated with disease- which have partly replicated-
especially on Chromosome 2. However despite ten years of work- no clear
genes inﬂuencing OA in humans have been uncovered in this way.
Candidate gene studies have proposed over 100 possible known genes as
being responsible. Sadly - most of these (e.g Calm1, VDR, Il-6,CILP and
FRZB) have not replicated in recent larger meta-analysis studies- and most
of the previous candidate gene literature can now be dismissed.
GWAS have been performed widely since 2007 and have led to the discov-
ery of over 600 gene loci in over 50 diseases. Although the gene variants
discovered are common they are of small individual effect. In some diseases
like macular degeneration and Crohns disease 20-40% of variance can be
explained- but more commonly - like in osteoporosis - less than 2% with
34 genes. Nevertheless the genes found- like in osteoporosis are commonly
key biological targets useful in therapeutics.
Early genome wide association studies of OA using 100,000 SNPS from
Japan and pooled GWAS of 550,000 from UK have added further candidates-
such as GDF5 and PGE2. The major robust and signiﬁcant ﬁnding across
all populations is the GDF5 gene- although it has a modest effect in
Europeans- this replicated consistently and is also a key gene for height-
and is a skeletal development gene and may have a role in hip dysplasia.
The largest published GWA studies of OA to date is from the EU funded
Treat-OA consortium (www.Treat-OA.eu) To date these meta-analyses have
shown for knee OA another deﬁnite gene locus in Chromosome 7- which
has 5 possible functional candidates. So far Major genes for BMD have not
been found to inﬂuence OA in meta-analyses. OA gene ﬁnding is proving
more diﬃcult than for BMD- - particularly at the hip - this may be because
of smaller sample sizes or the heterogeneity of the phenotype. It is clear
that further genes can only be found by pooling all the world GWAS
samples -and this is ongoing via the Treat-OA consortium.
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MOLECULAR EPIDEMIOLOGY OF OSTEOARTHRITIS AND BIOMARKERS
E. Slagboom
LUMC, Leiden, Netherlands
Osteoarthritis (OA) is the most prevalent musculoskeletal disorder and
is associated with gross functional impairment and disability among the
elderly. Risk factors for OA are age, body mass index and genetic predis-
position which may act interactively. Up until now there are no reliable
clinical biochemical markers to monitor disease activity over time or to
assess quantitative joint tissue remodeling and/or inﬂammatory processes.
Research that aims towards identiﬁcation of such sensitive markers of OA
may directly improve the disease management. Equally, a better insight into
the pathogenic process may eventually lead to new intervention strategies.
Moreover, most investigations focus on ﬁnding pathways that determine
risk for OA, however, insight is lacking on factors that keep people healthy.
We established a multidisciplinary research line which is applied to char-
acterize human populations for OA and aging biomarkers integrated with
genomics technologies. The OA disease population consists of sibling pairs
of the GARP study with symptomatic and radiographic OA in two or more
joint sites of the hand, spine (cervical or lumbar), knee or hip. Radiographic
OA was assessed according to the Kellgren/Lawrence (0-4) method, while
symptomatic OA of knee, hip and hands was deﬁned according to the
American College of Rheumatology (ACR) recommendations. Since this
population has OA data on most prevalent joint locations, biomarker levels
are not likely to be confounded by OA at joint locations for which data
is lacking. Furthermore, GARP provides enough OA heterogeneity to detect
variation, whereas distinct OA endpoints can be studied such as knee or
hip OA. To establish whether healthy survival and exceptional longevity
associate to healthy locomotor functions, molecular research is applied to
the Leiden Longevity Study (LLS) consisting of long-lived Caucasian siblings
with their offspring and the partners thereof. The survival beneﬁt of these
families is marked by a 30% excess survival observed in the proband, the
parental and the offspring generation
Molecular epidemiological tools are applied to the molecular data sets gen-
erated in GARP and LLS to elucidate predictive proﬁles that mark biological
ageing and/or OA risk in the population and to elucidate underlying mech-
anisms. As proof of principle we explored the possibility to discriminate
patients on the underlying pathophysiology of the different OA subtypes.
Among the markers measured, urinary CTX-II levels were most consistently
associated to cartilage damage, however, lacked speciﬁcity to reﬂect OA at
speciﬁc joint locations. Integrated analyses, however, of multiple markers of
cartilage and bone indicated speciﬁc molecular mechanisms among GARP
OA patients. More recently urinary CTX-II and serum COMP were measured
and analyzed in Leiden Longevity study and suggest that familial longevity
is associated with a favorable maintenance of the cartilage integrity with
age.
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OSTEOCHONDRAL ANGIOGENESIS: NEW THERAPEUTIC HORIZONS
D.A. Walsh
Univ. of Nottingham, Nottingham, United Kingdom
The relationship between structural change and symptoms in OA is incom-
pletely understood. Synovial and subchondral compartments are separated
in the normal knee, with the tidemark representing a barrier to diffusion,
and the articular cartilage and subchondral bone plate representing a
physical barrier to loading forces. In OA, this osteochondral barrier is
compromised, and osteochondral angiogenesis is increasingly recognised
as a key component of that structural change.
New blood vessels grow through channels from subchondral bone marrow
spaces into non-calciﬁed articular cartilage, both in human OA and in
animal models. Angiogenesis is accompanied by sensory nerve growth,
resulting in neurovascularisation of this usually avascular and insensate
structure. Nerve and blood vessel growth at the osteochondral junction
are associated with ﬁbrovascular replacement of the subchondral bone
marrow, and with growth factor expression in the subchondral bone spaces
and by articular chondrocytes. Increased expression of molecules such as
vascular endothelial growth factor, platelet derived growth factor and nerve
growth factor may drive blood vessel and nerve growth, whilst resistance
of the articular cartilage to vascularisation is reduced due to changes in
its matrix composition. Regulation of osteochondral angiogenesis appears
to be distinct from that in other joint structures, such as the synovium.
Angiogenesis is a key component of endochondral ossiﬁcation, resulting
in new bone formation around vascular channels at the osteochondral
junction, and of chondrophytes at the joint margin. Perforation of the
subchondral plate by vascular channels compromises the barrier between
synovial and subchondral spaces.
Vascularisation of the non-calciﬁed articular cartilage has been associated
with clinical symptoms and signs in OA. Osteochondral angiogenesis has
been targeted in animal models by preventing channel formation, or
inhibiting blood vessel growth. Blocking channel formation, for example by
metalloproteinase inhibition, reduces pain behaviour even in the presence
of osteophytes and chondropathy. Inhibition of blood vessel growth,
for example with the methionine aminopeptidase (MetAP)-2 inhibitor
PPI-2458, also reduces pain behaviour in the rat meniscal transection model
of OA. The unique matrix composition of the osteochondral junction raises
the potential to develop inhibitors of osteochondral angiogenesis with
more favourable side effect proﬁles than seen with angiogenesis inhibition
elsewhere. Further work is required to fully determine the relative contri-
butions to pain and joint damage, of angiogenesis at the osteochondral junc-
tion. Identifying aspects of OA structural change that lead to pain should
lead to focused strategies of disease modiﬁcation for symptomatic beneﬁt.
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METABOLIC DISEASES AND OA
P. Richette
Hôpital Lariboisière, Paris, France
Recent data have shown that primary osteoarthritis (OA) is not simply
a disease related to aging or mechanical stress of joints. Indeed, OA has
been linked in epidemiological studies not only to obesity but also to
other cardiovascular risk factors, namely, diabetes mellitus, dyslipidemia,
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hypertension, and insulin resistance, suggesting that systemic factors could
also play a role in the genesis of OA joint damage.
A number of deﬁned metabolic diseases may also lead to non-inﬂammatory
arthropathy with radiographic features predominantly of OA. The principal
conditions that predispose to secondary OA are ochronosis, wilson’s dis-
ease, acromegaly and hereditary hemochromatosis (HH). The most common
form of HH is an autosomal recessive iron overload disorder associated
with mutation of the HFE gene. Affected individuals may present with a
severe arthropathy mimicking OA, typically involving the second and third
metacarpophalangeal joints, which may seriously affect quality of life.
Other metabolic diseases, like chronic hypomagnesaemia or primary hyper-
parathyroidism may lead to deposition of calcium pyrophosphate crystals
within cartilage. These deposits, named chondrocalcinosis when identi-
ﬁed by X-Rays, are associated with OA, which may present with more
inﬂammatory symptoms, an atypical distribution and prominent cyst and
osteophyte formation on radiographs.
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NANOMEDICINE AND OSTEOARTHRITIS: WHAT CAN WE EXPECT FOR THE
FUTURE?
K. Yudoh1, R. Karasawa1, K. Masuko2, K. Shishido3, M. Takeuchi3,
S. Yamana4, H. Aoshima4, T. Kato1
1St. Marianna Univ. Sch. of Med., Kawasaki City, Japan; 2Sagami Women’s
Univ., Sagamihara City, Japan; 3Mitsubishi Corp., Tokyo, Japan; 4Vitamin C60
BioRes. Corp., Tokyo, Japan
Despite all the advances in bone and cartilage biology, particularly in
the recent bone and joint decade, there are still some deﬁciencies in our
understanding of the pathogenesis of osteoarthritis (OA), as well as our
ability to diagnose and treat OA. Nanomedicine is expected to improve
the ADL of patients with OA through the advances in the technology for
diagnosis and treatment.
(1) Oxidative DNA damage contributes to aging and degeneration of ar-
ticular cartilage. During the development of OA, mechanical and chemical
stresses on articular cartilage change the stable cellular activities of chon-
drocytes and produce excess amounts of reactive oxygen species (ROS) as
well as proinﬂammatory cytokines and chemokines. Studies have provided
ample conﬁrmation of the accumulation of ROS and the chondrocyte aging
in degenerated articular cartilage.
Our recent study revealed the potential involvement of accumulation of 8-
Oxoguanine, an oxidized form of guanine, and impairment of mitochondrial
DNA repair enzymes in the pathogenesis of OA. 8-Oxoguanine is produced
by ROS in large amounts in both DNA and nucleotide pools and is a major
causative lesion for mutagenesis by ROS in a variety of diseases.
We observed the increased level of 8-Oxoguanine and decreased level of
Ogg1 in osteoarthritic chondrocytes of degenerated cartilage in comparison
with chondrocytes of intact cartilage in animal models of OA and in patients
with OA, suggesting the involvement of the accumulation of 8-Oxoguanine
in articular chondrocytes and down-regulation of its repair enzyme Ogg1
in the degeneration of articular cartilage in OA. We found that over-
expression of mitochondria-targeted human hOgg1 in human osteoarthritis
chondrocytes prevents oxidant-induced mitochondrial dysfunction, OA re-
lating catabolic stress-induced caspase-9 activation and apoptosis in vitro.
Furthermore, hOgg1 silencing using siRNA reduced chondrocyte activity
and augments apoptosis in human ostearthritic chondrocytes.
(2) Application of nanotechnology to chondroprotection. In the previous
studies, we have focused on nanocarbon particle, fullerene (C60), which
acts a strong free radical scavenger, as an anti-oxidative agent, to prevent
the degeneration of articular cartilage in OA. We have demonstrated that
water-soluble fullerene has a potential as a protective agent against the
catabolic stress-induced degeneration of articular cartilage both in vitro
andin vivo OA models.
In this paper, we demonstrate that mitochondrial 8-Oxoguanine DNA
glycosylase regulates the cellular function and survival of osteoarthritic
chondrocytes in response to catabolic stresses in OA. In addition, we show
that C60 fullerene may inﬂuence the expressions of mitochondrial DNA
repair enzymes and their functions in osteoarthritic chondrocytes, suggest-
ing that C60 fullerene has a therapeutic potential, as a nanomedicine, to
protect against the degeneration of articular cartilage in OA. We would like
to conclude the pathomechanism of OA in terms of the chondrocyte ability
and function in response to oxidative stress by augmenting DNA repair.
(3) Application of bone and cartilage imaging. Magnetic resonance imag-
ing (MRI) is now thought an effective tool in the image diagnosis of OA.
However, spatial resolution of MRI is limited to a span of one to several
millimeters. While conventional X-ray imaging system has been used in
the image diagnosis of various diseases, cartilage cannot be depicted with
them. There has been a strong call for an X-ray imaging technology that can
depict cartilage. More recently, Kido K. et al. demonstrated a novel X-ray
imaging system which it would be easier to detect the onset of a disease,
to diagnose the stage of the disease, and to monitor the effect of treatment
for bone and cartilage diseases. We also show their excellent technology of
image diagnosis, an X-ray Talbot-Lau interferometry, for degenerated bone
and cartilage.
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REGENERATIVE MEDICINE: THE BIOLOGICAL REPAIR OF JOINT SURFACES
F. Luyten
Univ. Hosp. KULeuven, Leuven, Belgium
Regenerative Medicine aims to reconstruct or regenerate damaged or lost
tissue function due to trauma, disease or congenital defects, ideally without
tissue scarring. As articular cartilage does not heal, restoring damaged joint
surfaces has been a typical example where regmed approaches have been
explored extensively for over 15 years.
With the adoption of a new regulatory framework for Advanced Therapy
Medicinal Products (ATMP) at the end of 2007, also for cellular and/or
combinations products, the path of product development has become more
clear. Characterization of the cellular product by viability, identity, potency
and purity together with appropriate preclinical and toxicity studies, and
validation of a good manufacturing process (GMP) are all part of and critical
in this track of development. So far, one autologous cartilage cell product
has obtained central regulatory approval for the repair of symptomatic
articular cartilage defects in the knee. The data of the short and long term
follow up conﬁrm structural superiority over microfracture, considered
the standard of care. Clinical superiority over microfracture is particularly
striking for patients with a relatively recent medical history (less then 5
years).
Additional explorative trials for cartilage repair using variations on autolo-
gous cell based approaches, including the use of collagen membranes, have
provided valuable information about study design, mechanisms of repair
and clinical outcome and have revealed that further improvements could
be achieved. Besides expanded autologous articular chondrocytes, the use
of allogenic progenitor cell populations are now considered as an important
goal.
Some promising results have been reported in animal studies using pro-
genitor and mesenchymal cell populations (MSC) in post-traumatic models
of osteoarthritis (OA). However, before being able to evaluate the role of
cellular therapies in OA, more detailed information is needed on many
aspects including mechanisms of action, the fate of the cells, choice of cell
type and tissue origin, and culture parameters. Indeed, the mechanisms by
which MSC may contribute to tissue repair in OA are diverse and include
trophic effects, anti-inﬂammatory effects and direct tissue repair through
engraftment. The use of biomarkers to identify mechanistic events and
patients responding to treatment is an important step forward for these
more sophisticated regenerative approaches in OA.
In conclusion, there is hope for regenerative medicine, in particular in joint
an skeletal applications.
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IMPACT OF OSTEOARTHRITIS PAIN ON THE BRAIN
T.J. Schnitzer, A.V. Apkarian
Northwestern Univ. Feinberg Sch. of Med., Chicago, IL
Purpose: Chronic pain is a hallmark of osteoarthritis (OA), yet little is
known about its properties and representation in the brain. Previous
studies from our group in other pain states have demonstrated distinct
global and local brain morphological changes. The current investigations in
patients with OA were undertaken to compare this condition and ascertain
its speciﬁcity in comparison to other clinical chronic pain conditions.
Methods: Psychophysical measurements to examine the magnitude and
temporal properties of pain perception were coupled with fMRI to evaluate
brain activity in healthy controls and OA patients and relate brain activity to
clinical parameters of the disease. Voxel-based morphometry was utilized
to determine gray matter changes in OA and compared to other chronic
